MX383580B - Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos. - Google Patents
Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos.Info
- Publication number
- MX383580B MX383580B MX2019005308A MX2019005308A MX383580B MX 383580 B MX383580 B MX 383580B MX 2019005308 A MX2019005308 A MX 2019005308A MX 2019005308 A MX2019005308 A MX 2019005308A MX 383580 B MX383580 B MX 383580B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- treatment
- indols
- cartilage
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
(ver Fórmula). La presente invención se refiere a 9H-pirido[3,4-b]indoles sustituidos con 8-arilo y sustituidos con 8-heteroarilo de fórmula I, en la que A, E, G, R1 a R6 y R10 son como se definen en las reivindicaciones, que estimulan la condrogénesis y la síntesis de la matriz del cartílago y se pueden usar en el tratamiento de trastornos y afecciones del cartílago en los que se desea la regeneración del cartílago dañado, por ejemplo, enfermedades de las articulaciones tales como la osteoartritis. La invención se refiere además a procesos para la síntesis de los compuestos de fórmula I, su uso como productos farmacéuticos, y a composiciones farmacéuticas que los comprenden.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (en) | 2016-11-07 | 2016-11-07 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| PCT/EP2017/078026 WO2018083157A1 (en) | 2016-11-07 | 2017-11-02 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019005308A MX2019005308A (es) | 2019-08-05 |
| MX383580B true MX383580B (es) | 2025-03-14 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005308A MX383580B (es) | 2016-11-07 | 2017-11-02 | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos. |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US11130755B2 (es) |
| EP (3) | EP3318563A1 (es) |
| JP (1) | JP7046063B2 (es) |
| KR (1) | KR102490199B1 (es) |
| CN (1) | CN110382496B (es) |
| AR (1) | AR110136A1 (es) |
| AU (2) | AU2017353381B2 (es) |
| CL (1) | CL2019001251A1 (es) |
| CO (1) | CO2019005090A2 (es) |
| CR (1) | CR20190217A (es) |
| DK (1) | DK3535263T3 (es) |
| DO (1) | DOP2019000112A (es) |
| EA (1) | EA038365B1 (es) |
| EC (1) | ECSP19031458A (es) |
| ES (1) | ES2837765T3 (es) |
| HR (1) | HRP20201754T1 (es) |
| HU (1) | HUE052187T2 (es) |
| IL (1) | IL265982B (es) |
| LT (1) | LT3535263T (es) |
| MA (1) | MA45803B1 (es) |
| MX (1) | MX383580B (es) |
| MY (1) | MY189589A (es) |
| PE (1) | PE20191032A1 (es) |
| PH (1) | PH12019500997B1 (es) |
| PT (1) | PT3535263T (es) |
| RS (1) | RS61172B1 (es) |
| SG (1) | SG11201903195YA (es) |
| SI (1) | SI3535263T1 (es) |
| TN (1) | TN2019000143A1 (es) |
| TW (1) | TWI753966B (es) |
| UY (1) | UY37473A (es) |
| WO (1) | WO2018083157A1 (es) |
| ZA (1) | ZA201902111B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| WO2019136320A1 (en) | 2018-01-05 | 2019-07-11 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| CN112135613A (zh) * | 2018-03-20 | 2020-12-25 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| KR20220044721A (ko) * | 2019-08-06 | 2022-04-11 | 도메인 테라퓨틱스 | 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물 |
| CN114763347B (zh) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) * | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| ECSP951529A (es) | 1995-09-05 | 1997-05-16 | Compuestos farmaceuticos | |
| EP1134221A1 (en) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| US9248124B2 (en) | 2001-11-07 | 2016-02-02 | Millennium Pharmaceuticals, Inc. | Use of inhibitors of IκB kinase for the treatment of cancer |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| JP4626613B2 (ja) | 2004-08-04 | 2011-02-09 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子 |
| HRP20120643T1 (hr) | 2006-08-25 | 2012-08-31 | Ares Trading S.A. | Liječenje poremećaja hrskavice sa fgf-18 |
| WO2008132454A1 (en) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| FR2916380B1 (fr) * | 2007-05-21 | 2009-07-31 | Saint Gobain | Procede et dispositif de surmoulage d'un element vitre par une portion de joint comportant un insert, vitrage et insert notamment pour ce procede. |
| WO2010038153A1 (en) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Use of sox transcription factor acti\ators for stimulating chondrogenesis |
| US9962368B2 (en) * | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2455378A1 (en) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| JP5854492B2 (ja) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | 軟骨細胞分化誘導促進剤 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/en not_active Withdrawn
-
2017
- 2017-11-02 HR HRP20201754TT patent/HRP20201754T1/hr unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 EP EP20198613.0A patent/EP3792262B1/en active Active
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/hu unknown
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/ja active Active
- 2017-11-02 PH PH1/2019/500997A patent/PH12019500997B1/en unknown
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 MX MX2019005308A patent/MX383580B/es unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/ko active Active
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/da active
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/en not_active Ceased
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/es unknown
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/en active Active
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/lt unknown
- 2017-11-02 PT PT177943073T patent/PT3535263T/pt unknown
- 2017-11-02 SI SI201730476T patent/SI3535263T1/sl unknown
- 2017-11-02 RS RS20201512A patent/RS61172B1/sr unknown
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 ES ES17794307T patent/ES2837765T3/es active Active
- 2017-11-02 MA MA45803A patent/MA45803B1/fr unknown
- 2017-11-02 EA EA201991144A patent/EA038365B1/ru unknown
- 2017-11-02 CR CR20190217A patent/CR20190217A/es unknown
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/zh active Active
- 2017-11-03 TW TW106138038A patent/TWI753966B/zh active
- 2017-11-07 UY UY0001037473A patent/UY37473A/es not_active Application Discontinuation
- 2017-11-07 AR ARP170103083A patent/AR110136A1/es active IP Right Grant
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/es unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/es unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/es unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/es unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US12275733B2/en active Active
-
2025
- 2025-03-03 US US19/068,406 patent/US20250333412A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383580B (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| MX375925B (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| MX382331B (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer. | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| MX383804B (es) | Derivados de piperidina. | |
| MX378717B (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| MX387443B (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| HN2012000889A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| EA201001425A1 (ru) | Азаиндольные соединения для лечения заболеваний центральной нервной системы | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
| MX2018014164A (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico. | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| CY1120744T1 (el) | Παραγωγα οξικου οξεος αζαϊνδολης και η χρηση αυτων ως ρυθμιστων υποδοχεων προσταγλανδινης d2 | |
| BR112018004347A2 (pt) | derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida | |
| CY1118084T1 (el) | ΠΑΡΑΓΩΓΑ ΤΟΥ 7-(ΕΤΕΡΟΑΡΥΛ-ΑΜΙΝΟ)-6,7,8,9-ΤΕΤΡΑΫΔΡΟΠΥΡΙΔΟ[1,2-α]ΙΝΔΟΛΟ ΟΞΙΚΟΥ ΟΞΕΟΣ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΤΡΟΠΟΠΟΙΗΤΕΣ ΤΟΥ ΥΠΟΔΟΧΕΑ ΤΗΣ ΠΡΟΣΤΑΓΛΑΝΔΙΝΗΣ D2 | |
| MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. | |
| EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| EA202192092A3 (ru) | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos |